Hepatic Transcript Profiles of Cytochromes P450 Genes Predict Sex Differences in Drug Metabolism

James C. Fuscoe, Vikrant Vijay, Joseph P. Hanig, Tao Han, Lijun Ren, James J. Greenhaw, Richard D. Beger, Lisa M. Pence, and Qiang Shi

Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas (J.C.F, V.V., T.H., L.R., J.J.G., R.D.B., L.M.P., Q.S.); and Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (J.P.H.)
Running Title Page

Running title: Hepatic mRNA profiles predict sex different drug metabolism

Corresponding author: James C. Fuscoe, Ph.D., FDA-NCTR, 3900 NCTR Rd., Jefferson, AR 72079: Tel: 501-326-4398; Fax: 870-543-7682; Email: jfuscoe@gmail.com

Number of text pages: 44

Number of tables: 5

Number of figures: 7

Number of references: 58

Number of words in Abstract: 233

Number of words in Introduction: 770

Number of words in Discussion: 1814

Abbreviations:

ATP: adenosine triphosphate

Cmax: maximum serum concentration in humans receiving a clinical dose of the drug

Cyp: cytochrome P450

DMETs: drug metabolizing enzymes and transporters

DMSO: dimethyl sulfoxide

FDA: U.S. Food and Drug Administration

GLM: generalized linear model
HPLC: high-performance liquid chromatography

LDH: lactate dehydrogenase

NCBI: National Center for Biotechnology Information

NCTR: National Center for Toxicological Research

NIH: National Institutes of Health

PVDF: polyvinylidene difluoride

qPCR: quantitative polymerase chain reaction

qRT-PCR: quantitative real time polymerase chain reaction

RNASeq: RNA sequencing

t₁/₂: half-life
Abstract

Safety assessments of new drug candidates are an important part of the drug development and approval process. Often, possible sex-associated susceptibilities are not adequately addressed, and better assessment tools are needed. We hypothesized that hepatic transcript profiles of cytochrome P450 (Cyp) enzymes can be used to predict sex-associated differences in drug metabolism, and possible adverse events. Comprehensive hepatic transcript profiles were generated for F344 rats of both sexes at nine ages, from 2 weeks (pre-weaning) to 104 weeks (elderly). Large differences in the transcript profiles of 29 drug metabolizing enzymes and transporters (DMETs) were found between adult males and females (8-52 weeks). Using the PharmaPendium database, 41 drugs were found to be metabolized by one or two Cyp enzymes encoded by sexually dimorphic mRNAs, and thus were candidates for evaluation of possible sexually dimorphic metabolism and/or toxicities. Suspension cultures of primary hepatocytes from three male and three female adult rats (10-13 weeks old) were used to evaluate the metabolism of 11 drugs predicted to have sexually dimorphic metabolism. The pharmacokinetics of the drug or its metabolite was analyzed by liquid chromatography/tandem mass spectrometry using multiple reaction monitoring. Of those drugs with adequate metabolism, the predicted significant sex-different metabolism was found for six of seven drugs, with half-lives 37%-400% longer in female hepatocytes than in male hepatocytes. Thus, in this rat model, transcript profiles may allow identification of potential sex-related differences in drug metabolism.
Significance Statement

The present study showed that sex-different expression of genes coding for drug metabolizing enzymes, specifically cytochrome P450s, could be used to predict sex-different drug metabolism, and, thus, provide a new tool for protecting susceptible subpopulations from possible adverse drug events.
Preclinical safety assessments are a crucial step in assuring the development of safe and effective medical products. Despite large investments of resources in this process, drugs can still enter the market with safety liabilities that result in patient injury and even death (Moore et al., 2007). An analysis of the success rate of drugs at phase III clinical trials and at submission to the U.S. Food and Drug Administration (FDA) has shown a decline to about 50% in recent years. Of 83 phase III and submission failures between 2007 and 2010, 66% were efficacy related, but a substantial portion (21%) was due to safety issues (Arrowsmith, 2011). Thus, even with extensive preclinical testing and computational approaches, there is a need for better prediction of drug safety in humans.

Preclinical drug assessments may also benefit from consideration of sex as a biological variable. For example, the U.S. General Accounting Office reviewed ten prescription drugs withdrawn from the market between 1997 and 2000 for safety reasons (GAO, 2001). The adverse events associated with the withdrawal of eight of these drugs appeared to present a greater risk for women, suggesting inadequate understanding of sex-related differences. In fact, despite growing recognition for the need to include both sexes in drug evaluation (NIH, 1994; NIH, 2000; Institute of Medicine, 2010), sex-bias in preclinical research is a continuing problem, with single-sex studies of male animals outnumbering those of females by substantial margins (Zucker and Beery, 2010; Beery and Zucker, 2011). In 2013, the FDA approved a label change for the sleeping aid medication zolpidem tartrate because women were found to be more susceptible to next-day impairment (FDA, 2013), possibly by differences in pharmacokinetics or pharmacodynamics (Greenblatt et al., 2004). This marked the first time that FDA had...
recommended different dosing for men and women for a drug that was intended for both sexes. Thus, there is a clear need to consider possible sex differences from the beginning of the drug development process, including preclinical studies. The NIH is encouraging such studies by requiring research plans that balance male and female animals and cells in preclinical studies (Clayton and Collins, 2014).

Sex differences in the pharmacokinetics and pharmacodynamics of pharmaceutical drugs have recently been reviewed (Soldin and Mattison, 2009; Waxman and Holloway, 2009; Soldin et al., 2011), and show that men and women may differ in how the body handles a specific drug. Much of the data on sex differences, however, is obtained by post hoc analysis so that firm conclusions are often difficult to draw. The inclusion of explicit sex-difference analysis in future clinical and preclinical studies will be essential for the optimal safe and effective use of medical products for men and women.

To address the knowledge gap that exists for determining possible sex differences during drug development, we hypothesized that hepatic transcript profiles of cytochrome P450 (Cyp) enzymes could be used to predict sex-associated differences in drug metabolism. We tested this hypothesis in a rat model system because of the availability of extensive hepatic transcript data (Kwekel et al., 2010; Yu et al., 2014) to make predictions and primary hepatocyte culture techniques for testing the predictions. In previous studies (Kwekel et al., 2010; Kwekel et al., 2013a; Kwekel et al., 2013b; Yu et al., 2014) notable sex- and age-differences in the expression of genes in the liver, kidney, and nine other tissues in normal rats, including genes crucial to drug
metabolism, were found. Dramatic differences in gene expression were found between male and female rats, including the rat orthologs to human enzymes CYP1A2, CYP2D6, CYP2C9, CYP2E1, and CYP3A4. Collectively, the enzymes encoded by these genes are responsible for the metabolism of approximately 75% of all prescribed drugs (Zanger and Schwab, 2013). The functional capacity of drug metabolizing pathways is proportional to the expression levels of individual proteins or enzymes contained within those pathways. Although measurement of individual enzyme activities is a challenging task, measurement of the expression level of genes coding for these enzymes can be done in a relatively straight-forward manner by microarray or RNASeq analysis. Although gene expression would be an indirect measure of enzyme activity, if differences exist in the expression of these genes between males and females, the functional capacity of these drug metabolizing pathways may vary as well, potentially producing differences in the drug's efficacy or toxicity. In this study, sex-different expression of hepatic transcripts coding for Cyp enzymes were identified in rat, along with their target drugs, and the predicted sex-difference in drug metabolism was tested in male and female rat primary hepatocytes. Results suggest that hepatic transcript profiles may allow insights into possible sex-differences in drug metabolism.
Materials and Methods

Development of a Comprehensive List of Genes Encoding Drug Metabolizing Enzymes and Transporters (DMETs) Along with Their Drug Substrates

As a first step for this study, a comprehensive list of DMETs was needed so that we could examine their expression in rat liver. To our knowledge, there is no resource where we can find a comprehensive list of DMETs. A list of DMETs and substrate drugs was obtained from “metabolizing enzymes and transporter data” module of PharmaPendium (Elsevier, Amsterdam, NL). PharmaPendium is a commercial product, which provides comprehensive access to searchable regulatory documents from the FDA and European Medicines Agency, including the U.S. FDA Adverse Event Reporting System, drug safety, pharmacokinetic, efficacy, activity, and metabolizing enzyme and transporter data. The data sources of PharmaPendium for drug metabolizing enzymes and transporters include FDA approval packages, EMA approval documents, FDA Advisory Committee Documents, and PharmaPendium Published MET (literature sources) (https://service.elsevier.com/app/answers/detail/a_id/29412/supporthub/pharmapendium/kw/source/). Although, PharmaPendium is a good resource for information about the DMETs and drug substrate, the gene symbols and enzyme names are not standardized/updated and contain mixed symbols/names. A rigorous manual curation of these gene symbols was performed to develop a comprehensive list of genes encoding DMETs in the rat. In brief, all data related to DMETs and their substrate for all species was exported from PharmaPendium (PharmaPendium master data - a total of 264312 entries (rows) and 26 columns; accessed on 2nd June 2015). From this list, unique entries based on “Drug name”, “Data Type”, “Enzyme/Transporter”, and “Species” columns were retained (25646 entries). Then, unique entries based on only
“Enzyme/Transporter”, and “Species” were extracted (925 entries). All non-specific names were then removed and DMETs for only rat and humans were retained (443 entries). These gene names/symbols were mapped to the most up-to-date human and rat gene annotations using National Center for Biotechnology Information (NCBI) “Gene” module, and manual update/correction of DMETs gene symbols was performed to match the rat gene symbol annotation. These gene symbols were updated/corrected/annotated for the rat in six steps: 1) if the symbols were an exact match to the most up-to-date symbols from NCBI, then they were kept as is; 2) some symbols were old notations and they were updated with the latest annotation; 3) some of the DMETs had gene names (e.g., “alcohol dehydrogenase”) instead of gene symbols; they were substituted with all the isoforms of that gene; 4) genes which did not have a corresponding orthologous gene symbol in rat were substituted by homologous genes (to human genes) using Homologene module of NCBI; 5) some gene symbols were misspelled, which were corrected manually; and 6) two genes had no corresponding exact match or orthologous or homologous genes in rats and were deleted. After performing all these steps, a final list of 336 genes encoding DMETs was prepared (Supplemental Table 1).

The PharmaPendium master data contained information on 1197 unique drugs and their associated metabolizing DMETs (Gene symbols). These data were extracted to allow association between drugs and the 336 DMETs.

Gene Expression Data and Statistical Comparison between Female and Male
The expression profiles of 336 DMETs were examined in a comprehensive whole genome hepatic transcript profile data set of F344 rats, which contains data from nine ages (2 weeks to 2 years of age) and both sexes (Kwekel et al., 2010). This data set, available at the NCBI Gene Expression Omnibus database with accession GEO21335, contained transcript profiles for 298 of these 336 DMET genes (Supplemental Table 1) and these normalized gene expression profiles were extracted for further analysis. Principal component analysis was performed in ArrayTrack (Tong et al., 2003; Fang et al., 2009), the FDA’s relational database for genomic data storage, processing, analysis, and visualization on log2-tranformed, normalized intensity values. ArrayTrack is free and publicly available (FDA, 2016). Statistical comparisons (t-test) between expression data of female (F) and male (M) for each of four adult age groups (8, 15, 21, and 52 weeks of age) were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Genes were considered to be differentially expressed between female and male at any one of the four ages, if the t-test p-value was <0.05 and fold ratio (F/M or M/F) was >2. Genes which were differentially expressed between female and male rats at all four adult ages were considered as sexually dimorphic genes for adult rats (Supplemental Table 2).

Animal Care

Fischer 344 rats (10–13 weeks of age; body weights of females were 160-180 g and males 260-280 g) were provided by the FDA National Center for Toxicological Research (NCTR) breeding colony. Animal care and experimental procedures were approved by the NCTR Institutional Animal Care and Use Committee. The rats were separated by sex and group-housed in polycarbonate cages using hardwood chip bedding. Filtered tap water was provided ad libitum and animals were fed NIH-41 irradiated diet ad libitum. Environmental controls were set to
maintain temperature at 22 ± 4°C, with relative humidity of 40-70% with a 12 hr light/dark cycle.

**Rat Hepatocyte Isolation**

A two-step perfusion method, as detailed in a previous publication, was used to isolate rat hepatocytes (Shi et al., 2011). Briefly, sodium pentobarbital (75 mg/kg, i.p.) was used to anesthetize the rat, and the liver was perfused via a catheter inserted into the inferior vena cava. The buffer was composed of 137 mM NaCl, 5.4 mM KCl, 0.5 mM KH$_2$PO$_4$, 0.6 mM Na$_2$PO$_4$, 25 mM NaHCO$_3$, 5 mM glucose, 5 μg/ml bovine insulin, 50 unit/ml penicillin and 50 μg/ml streptomycin. After approximately 10 min, 0.03% collagenase (type IV), 2 mM CaCl$_2$ and 0.01% soybean trypsin inhibitor were added to the perfusion buffer. The digested liver was homogenized and the suspension was centrifuged at 50g for 3 min. The pellets were resuspended in 90% isotonic Percoll solution (pH 7.0) and centrifuged at 100g for 8 min to purify the hepatocyte. Finally, the cells were suspended in William’s E medium supplemented with 5 μg/ml insulin, 5 μg/ml holo-transferrin, 25 nM dexamethasone, and 5 ng/ml sodium selenous acid. The cells were immediately used for suspension culture or were plated for prolonged culture as monolayers. All experiments were repeated using cells from at least three males and three females.

**Hepatocytes in Suspension Culture for Drug Metabolism Measurements**

The cells were diluted to 2 x 10$^6$ cell/ml and placed in 96-well plates (50 μl per well). The test drugs were obtained from Sigma-Aldrich (Saint Louis, MO), and were of USP reference
standard quality. Stock solutions were freshly prepared in dimethyl sulfoxide (DMSO) and diluted at 1:1000 using culture medium to achieve 2-fold the final treatment concentrations. This working solution was added to the 96 well plate (50 µl per well) containing cell suspensions. The final concentrations in the cultures were: 1 µM for buspirone, fentanyl, glimepiride, irinotecan, pravastatin, tamsulosin, and terfenadine; and 5 µM for azelastine, doxorubicin, and tazarotene. The compound 7-ethoxycoumarin (2 µM) was used as a positive control. The cells were placed on a microplate shaker in an incubator and cultured under 5% CO\textsubscript{2} at 37°C. After 5, 15, 30, 60, 90, and 120 min, 100 µl acetonitrile containing 50 ng/ml carbamazepine and 100 ng/ml tolbutamide were added to the wells to stop the reaction. The plates were placed at 4°C for 30 min, and then centrifuged at 800g for 10 min. Part of the supernatant (135 µl) was transferred to a new 96-well plate and the samples were dried using a SpeedVac under 4°C. The samples were then shipped on dry ice to Sano Informed Prescribing, Inc. (Franklin, TN) for measuring the drug/metabolite levels. Hepatocytes from three male and three female rats were prepared from untreated control cultures by centrifugation and stored at -80°C for qPCR and Western analysis.

**Hepatocytes Cultured as Monolayers for Drug Cytotoxicity Determination**

The hepatocytes were diluted to 2 x 10^5 cell/ml and then seeded at a density of 25,000 cells per well in white 96-well plates coated with type I collagen. The cells were incubated overnight at 37°C under a relative humidity of 95% and 5% CO\textsubscript{2}. The original culture medium was discarded and replaced with new medium containing the test drugs. The test compounds were freshly prepared as 1000X stock solutions in DMSO. The final concentrations of test drugs were 1, 2, 4, 6, 8, 10, 15, 20, 25, and 30-fold the maximum serum concentration in humans receiving a clinical dose of the drug (C\textsubscript{max} total concentration). Ideally, the concentrations to be tested in
cultured hepatocytes should mimic the liver tissue levels of the drugs. However, the liver concentrations of most drugs are unknown. A literature survey found that many drugs accumulated in the liver at concentrations of 10- to 30-fold Cmax (McIntyre, 2014; Venuto et al., 2017; Paech et al., 2018). It was therefore decided that a threshold of 30-fold Cmax would be used in this study. Cmax values for the set of 33 drugs metabolized by one or two Cyp enzymes encoded by sexually dimorphic mRNAs that were soluble in DMSO and commercially available are shown in Supplemental Table 3. DMSO (0.1%) was used as the vehicle control. After 8 and 24 h, three cytotoxicity endpoints were measured as described below.

Cytotoxicity Endpoints

Adenosine triphosphate (ATP) levels and Caspase 3/7 activity were measured using the CellTiter-Glo Luminescent Cell Viability Assay kit and Caspase-Glo 3/7 Assay kit (Promega, Madison, WI), respectively. Briefly, half of the medium was removed and 50 µl per well assay buffer was added. After 30 min, the luminescence signal was determined using a Tecan plate reader (Infinite M200 PRO). The signal from DMSO-treated cells was set as 100% (Zhang et al., 2018). Lactate dehydrogenase (LDH) release was measured using a procedure detailed in previous publications (Shi et al., 2011; Zhang et al., 2018). Briefly, 7 µl culture medium were taken to measure the leaked LDH, then the cells were lysed using 1% Triton X-100 to determine the total LDH activity. The ratio between leaked LDH and total LDH activity was used to calculate cell viability (Shi et al., 2011; Zhang et al., 2018).
Confirmation of Differentially Expressed Cyp Genes in Primary Hepatocytes by Quantitative Real Time PCR (qRT-PCR)

RNA samples were extracted from both monolayer and suspension cell cultures of untreated rat liver primary hepatocytes using Qiagen miRNeasy Mini Kits (Qiagen, Valencia, CA) following the manufacturer’s protocol. Monolayer cell culture samples were taken for RNA extraction after 0, 4, 20, 22, 24, and 26 hr of culture. Suspension cell culture samples were taken for RNA extraction after 0, 30, 60, 90, and 120 min. RNA quality was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and RNA integrity numbers ranged from 8.6-10, with an average of 9.3. These RNA samples were used to assess the expression of four Cyp genes (Cyp2c7, Cyp2c11, Cyp3a2, and Cyp3a62) which showed hepatic sexual dimorphism in a previous in vivo rat study (Kwekel et al., 2010; Yu et al., 2014). TaqMan gene expression probes for these Cyp mRNAs (Cyp2c7, Rn01529602_mH; Cyp2c11, Rn01502203_m1; Cyp3a2, Rn00756461_m1 and Cyp3a62, Rn01409578_m1) and endogenous control, Gapdh (Rn1775763_g1), were purchased from Thermo Fisher Scientific, Inc. (Hanover Park, IL). In brief, 900 ng total RNA from each sample were reverse transcribed to cDNA using the High Capacity RNA-to-cDNA Kit (Thermo Fisher) in a 96-well plate on a GeneAmp PCR System 9700 (Thermo Fisher). Each cDNA sample was then diluted 10-fold to 200 µl. Nine microliters of diluted cDNA sample was used for real-time PCR in a 20 µl reaction on an ABI 7900HT Fast Real-Time PCR System using TaqMan Universal Master Mix II with UNG kit (Thermo Fisher). Hepatocyte cultures from three male and three female rats were used for qRT-PCR and each culture was measured in duplicate. The $2^{-\Delta\Delta Ct}$ value (Livak and Schmittgen, 2001) of each sample was normalized to the lowest expression value for each gene before downstream analysis. These normalized values were used to compute the expression changes between sexes at the different
Western Blot Analysis

Monolayer cell culture samples were taken for protein extraction after 0, 4, 20, 22, 24, and 26 hr of culture. Suspension cell culture samples were taken for protein extraction after 0, 30, 60, 90, and 120 min. The hepatocytes were lysed and centrifuged as detailed previously (Weng et al., 2015). The resulting proteins were mixed with Laemmli buffer (Laemmli, 1970) and heated in a water bath at 95°C for 5 min before sodium dodecyl sulfate polyacrylamide gel electrophoresis. Thirty micrograms of protein were loaded in each lane and transferred to polyvinylidene difluoride (PVDF) membranes after electrophoresis. The primary monoclonal antibodies against rat CYP3A2 (catalog number P3A2PT from Detroit R&D, Inc, Detroit, MI) or CYP2C11 (catalog number P2C11PT from Detroit R&D, Inc) were mixed with the anti-actin antibody (catalog number ab3280 from Abcam) and incubated with the PVDF membrane for about 18 hr. All the primary antibodies were diluted 1000-fold for use. The membrane was then incubated with the secondary antibody for 1 hr, and the bands were visualized using an Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA).

Measurement of Drugs in Hepatocyte Suspension Cultures

Drug/metabolite measurements were performed by Sano Informed Prescribing (currently known as Precera Bioscience, Franklin, TN). All samples were analyzed via electrospray ionization on a Sciex QTRAP 5500 (Foster City, CA) instrument that was coupled with Shimadzu LC-30AD.
pumps (Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Analytes were separated by gradient elution using a Phenomenex C18 2.1 x 50 mm, 1.7 µm column (Torrance, CA) thermostated at 50°C. High-performance liquid chromatography (HPLC) mobile phase A was 10 mM ammonium formate in water and mobile phase B was 0.1% formic acid in acetonitrile. The gradient started at 30% B after a 0.2 min hold and was linearly increased to 90% B over 0.8 min; held at 90% B for 0.5 min and returned to 30% B in 0.1 min followed by a re-equilibration (0.9 min). At the time of analysis, the samples were reconstituted with initial mobile phase. The total run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. The source temperature was set at 500°C and mass spectral analyses were performed using multiple reaction monitoring, with transitions and voltages specific for each compound utilizing a TurboV source (Table 1). All data were collected using Sciex Analyst 1.6.2 and analyzed using MultiQuant 3.0.1 software. Each compound was assayed in triplicate within the same 96-well plate.

**Calculation of Half-lives for Drugs**

Half-life was calculated using elimination rate constant (λ, which is the slope of drug concentration during incubation with the primary hepatocytes) from a concentration-time plot. The concentration of drugs in hepatocyte culture was measured at 5, 15, 30, 60, 90 and 120 min for both sexes (n=3 rats for each sex; 3 technical replicates for each culture condition, which were averaged). The concentration of drugs at each timepoint was transformed into percent remaining with respect to the 5-min time point, for each sex. The percent remaining data were converted to natural logarithm values to perform statistics using SAS/STAT software, version 14.1 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA). The calculation of
slope for individual male and female rats and testing for heterogeneity (or homogeneity) of slopes of regression line between males and females was performed using a generalized linear model procedure (Proc GLM) in SAS. In brief, the GLM procedure used least squares analysis to fit the simple linear regression models and simultaneously estimate the intercepts and slopes for all rats. These slopes were used to calculate half-life (t½) of each drug for all male and female rats (n=3) using the formula: t½ = ln(2)/λ. Further, the half-life of each drug was compared between male and female rats (n=3) using the t-test. Additionally, the amount of drug remaining at each timepoint was also compared between male and female rats using the t-test.

Comparison of slopes between male and female was performed using time and concentration as the main effect as well as the interaction (time*concentration) in the model to calculate an overall slope from the concentration-time plot using data from 3 male or 3 female rats for each time point. If the deviations of the groups' slopes from the overall slope were not all zero and the interaction effect was significant (p<0.05), the slopes were not equal and there was significant difference between the slopes (λ) for male and female drug metabolism over time.

Half-life was not calculated for terfenadine since formation of fexofenadine (major metabolite of terfenadine) was measured to assess the metabolism of terfenadine. A statistical difference in the slopes of formation of fexofenadine to test heterogeneity (or homogeneity) of slopes of regression line between male and female rats was determined using simple linear regression as described above (using the proc GLM procedure in SAS).
Results

Sex-biased Hepatic Expression of DMET Genes

Principal component analysis, utilizing the expression profiles of 298 DMET genes, was used to examine hepatic DMET gene expression across the lifespan and between the sexes of F344 rats. The DMET gene expression profile varies with both age and sex, with the largest sex difference observed between adults (8-52 weeks of age) (Fig. 1). Twenty-nine DMET genes were found to be differentially expressed between male and female adults at all four ages (8, 15, 21, and 52 weeks of age), with 17 expressed at a higher level in males than females (Table 2) and 12 expressed at a higher level in females than males (Table 3). These included genes involved in phase I and phase II metabolism, as well as transporters. Genes with the highest expression in males compared to females were Sult1e1, Cyp2a2, Cyp2c13, Cyp2c11 and Cyp3a2 with a range of fold-differences of 216-2497. The genes with the highest expression in females compared to males were Abcc3, Sult2a1, Abcd2, Adh6 and Cyp2c12 with a range of fold-differences of 7.6-346. The 29 enzymes encoded by these differentially expressed genes metabolize or transport more than 600 drugs (Tables 2 and 3; Supplemental Table 2).

Drugs Metabolized by DMETs that Are Encoded by Sex-biased Genes

Because a large number of drugs (>600) are metabolized by these sexually dimorphic DMETs and many drugs are metabolized/transported by multiple enzymes/transporters, as a first step in evaluating if expression patterns of DMET genes can be used to predict drug metabolism differences, we focused on drugs that are metabolized by only one or two cytochrome P450s (Cyp) encoded by sex-different Cyp mRNAs. Using Supplemental Table 2, 41 such drugs were
identified and they are metabolized by CYP3A2, CYP2C11, CYP3A62, or CYP2C7 (Table 4). The 41 drugs encompass a large variety of drug classes and include antihistamines, antineoplastics, and analgesics.

Prediction of Sex-biased Drug Metabolism Based on Differential Gene Expression Profile

Based upon the differential gene expression levels of these Cyps in males and females, we hypothesized that drug metabolism dependent on these Cyps would be higher in the sex with the higher level of the Cyp mRNA. Eleven of the drugs in Table 4 were selected for testing of this hypothesis in male and female rat primary hepatocytes: doxorubicin, irinotecan, phenytoin, azelastine, buspirone, fentanyl, glimepiride, pravastatin, tamsulosin, terfenadine, and tazarotene. Selection criteria included a diversity of drug classes and drugs metabolized by at least one of the sexually dimorphic Cyps.

Testing of Predictions of Sex-biased Drug Metabolism in Male and Female Primary Rat Hepatocytes

Hepatocytes were isolated from male and female adult F344 rats of 10-13 weeks of age for analysis of sex-different drug metabolism.

Verification of Sex-biased Cyp Gene Expression in Primary Rat Hepatocytes. To verify that the cultured primary rat hepatocytes expressed the same relative sex-different levels of Cyp mRNAs as the liver of F344 rats, Cyp2c7, Cyp2c11, Cyp3a2, and Cyp3a62 mRNAs were measured during the 2 hr cell incubation period in both the suspension cultures (used for drug
metabolism measurements) and monolayer cultures (used for cytotoxicity measurements). As can be seen in Fig. 2 (A-D), the relative levels of these Cyp mRNAs in suspension cultures were similar to what was reported in the livers of F344 rats (Tables 2 and 3). Cyp3a2 and Cyp2c11 mRNAs were expressed in male primary hepatocytes and liver at thousands of times higher levels than in females. The qPCR measurements in the primary hepatocytes showed a larger difference between males and females (~20,000-fold difference for Cyp2c11 and ~11,000-fold difference for Cyp3a2) than the microarray measurements (~2200-fold for Cyp2c11 and ~2500-fold for Cyp3a2), possibly because of the higher sensitivity and dynamic range of the qPCR assay compared to the microarray (Kwekel et al., 2010) method. Cyp3a62 mRNA was expressed 5-6 fold higher in both male primary hepatocytes and liver than in female hepatocytes and liver. Cyp2c7 mRNA was expressed 3-5 fold higher in female primary hepatocytes and liver than in male primary hepatocytes and liver. Stable levels of each Cyp mRNA were maintained in both male and female cells during the full 2 hr incubation period. Similar and consistent expression differences of the Cyp mRNAs were found in the monolayer cultures with the fold-difference between male and female levels for Cyp3a2, Cyp2c11, Cyp3a62, and Cyp2c7 being 12,000, 39,000, 8.7, and 2.8, respectively, although there was significant decline in absolute expression by 20 hr (Supplemental Fig 1). Thus, the primary hepatocytes from male and female rats mimic relative mRNA levels of the intact rat liver.

Sex-biased CYP Protein Expression in Primary Rat Hepatocytes. Antibodies were commercially available for two of the rat CYP proteins (CYP3A2 and CYP2C11) encoded by sexually dimorphic mRNAs. Western blot analysis of extracts from male and female primary hepatocytes during the 2 hr incubation of suspension cultures showed higher levels of both proteins in male cells than female cells (Fig. 3A-B), with the female cells having undetectable
levels of these proteins. Stable levels of the CYP proteins were maintained in the male cells during the full 2 hr incubation period. Similarly, stable sex-different expression of the CYP proteins was seen in the cultures of attached cells used for cytotoxicity assays (Supplemental Fig. 2), with the proteins not detectable in female cells. Thus, the primary hepatocytes are expressing sex-different amounts of CYP proteins consistent with the relative levels of hepatic Cyp mRNA in male and female F344 rats.

**Drug Metabolism in Male and Female Primary Rat Hepatocytes.**

Eleven of the drugs with predicted sex-different Cyp metabolism were incubated with suspension cultures of primary hepatocytes from adult male and female F344 rats for 2 hr. Drug concentration remaining was measured at six timepoints (5, 15, 30, 60, 90, and 120 min) during this period and half-lives were determined. The concentration of terfenadine could not accurately be measured, and therefore, it was not possible to calculate the half-life ($t_{1/2}$) for the compound. Instead, the formation of its Cyp3a2 metabolite fexofenadine was measured. The kinetics of metabolism of each drug (except terfenadine) are shown in Fig. 4 and Fig. 5. The formation of fexofenadine from terfenadine during the 2 hr incubation is shown in Fig. 6.

**Three Drugs with Long Half-lives.** Three of the 11 drugs were not appreciably metabolized by either male or female rat primary hepatocytes during the 2 hr incubation period (Fig. 4C, doxorubicin; Fig. 4F, irinotecan; and Fig. 4G, phenytoin). The extent of metabolism of irinotecan and phenytoin was less than 10%, and the extent of metabolism of doxorubicin was less than 30%. Thus, accurate half-lives and possible differences between males and females could not be determined for these three drugs.
Sexually Dimorphic Metabolism of Six of Seven Drugs. The metabolism of azelastine, buspirone, fentanyl, glimepiride, pravastatin, and tamsulosin over the 2 hr incubation period in primary rat hepatocytes is shown in Fig. 4A, B, D, E, H, and I, respectively. With the exception of the four drugs discussed above (terfenadine, irinotecan, phenytoin, and doxorubicin), the half-lives of 7 drugs were determined and are shown in Table 5. Five drugs showed the predicted sexual dimorphism of greater metabolic rate in males than females (azelastine, 75% slower in females; buspirone, 89% slower in females; fentanyl, 49% slower in females; glimepiride, 70% slower in females; and tamsulosin, 39% slower in females) with p values <0.05.

Because of difficulties in consistently measuring terfenadine, the formation of fexofenadine, the Cyp3a2 major metabolite of terfenadine, was measured in male and female primary rat hepatocyte cultures. The kinetics of the metabolism in hepatocytes from males and females is shown in Fig. 6. The formation of fexofenadine was significantly more rapid in males than females with a slope more than four times greater in males than females (p< 0.0001). Thus, male metabolism of terfenadine was more rapid than female, as predicted from the transcript data.

The metabolism of tazarotene appeared to be rapid and identical in male and female rat primary hepatocytes (male, t_{1/2} =17 min; female, t_{1/2} =16 min, Table 5 and Fig. 5A), with no apparent sex-difference. A literature review revealed that tazarotene is hydrolyzed by esterases in liver, as well as the blood, of both humans and rats to its active metabolite, tazarotenic acid (Madhu et al., 1997). The formation of tazarotenic acid from tazarotene was, therefore, examined in both male and female rat primary hepatocytes. As shown in Fig. 5B, both male and female hepatocytes
rapidly form tazarotenic acid from tazarotene, with the reaction being essentially complete by <20 min. Thus, tazarotene was rapidly metabolized by esterase whose expression was not different between the sexes.

In summary, sex different metabolism was shown for six of the eleven drugs predicted to have sex different metabolism based on relative transcript levels of Cyp genes. Of the five drugs for which sex different metabolism could not be shown, three (irinotecan, phenytoin, and doxorubicin) were too slowly metabolized during the 2 hr incubation period in the hepatocyte system to accurately measure the half-life and one (tazarotene) was rapidly metabolized by an enzyme whose gene expression was not sexually dimorphic. The remaining drug, pravastatin, failed to show the predicted sexually dimorphic metabolism, although a relatively large, but not statistically significant, sex difference was observed. Thus, excluding the 4 drugs that were too slowly or rapidly metabolized, six of seven drugs (86%) were shown to have sexually dimorphic metabolism as predicted by our analysis of gene expression data.

Cytotoxicity of Drugs in Primary Rat Hepatocytes.

Of the 41 drugs predicted to have sexually dimorphic metabolism based on the sex difference in expression of Cyp mRNAs, 33 (Table 4) were chosen for cytotoxicity evaluation based on solubility in DMSO and availability. Three indicators of cytotoxicity were tested: Caspase 3/7 activity (indicator of apoptosis), LDH release from cells (indicator of necrosis), and cellular ATP concentration (indicator of energy dysregulation). An initial test on primary hepatocytes from one male and one female rat showed no toxicity of 14 drugs (amlodipine, buspirone, cetirizine,
digoxin, ebastine, fentanyl, flunisolide, levobupivacaine, lidocaine, loratadine, medroxyprogesterone, mometasone, norethindrone, and oxybutynin) in any of the assays at doses ranging from Cmax to 30x Cmax. The remaining 19 drugs (Table 4) were tested in the three assays using primary hepatocytes from three male and three female rats. Only two drugs showed significant toxicity in any assay at doses ranging from Cmax to 30x Cmax. Doxorubicin and terfenadine were both toxic in the LDH assay (Fig. 7). The decrease in the measured LDH leakage at higher concentrations of doxorubicin is likely because the released LDH is degraded over time. Doxorubicin was only toxic to primary hepatocytes from male rats at the doses tested, while terfenadine was toxic to primary hepatocytes from both male and female rats. Hepatocytes from female rats were more sensitive to terfenadine, however, than those from male rats.
Discussion

Transcriptomic profiling has become a routine, relatively inexpensive, and straightforward technique to gain a comprehensive picture of gene expression in tissues under a variety of conditions, including disease and aging. From such studies, insights have been gained as to mechanisms of disease, development of biomarkers, and possible treatments/interventions (van ’t Veer et al., 2002; Karczewski and Snyder, 2018). In addition, transcript profiling of tissues has revealed sex-differences in gene expression, including genes coding for DMETs, in both model organisms (Yu et al., 2014) and humans (Yang et al., 2012; Tukiainen et al., 2017). On one hand, transcriptomics has the advantage of being high-throughput, relatively inexpensive and providing global insight into differential expression of genes (either due to inherent difference or in response to external agents) resulting in the elucidation of different pathways (and mechanism) involved. On the other hand, just examining the transcriptomics profiling alone may not provide a complete picture of the full mechanism, as the translational products of transcripts, the proteins, are the one performing the major tasks. Further, there are various other processes such as alternative splicing, protein modifications (e.g., glycosylation and folding), phosphorylation status, and translocation to site of activity, that play a major role in protein/enzyme activity. All the aforementioned processes have the potential for sex- and/or age-related differences. Predicting biological outcomes is not easy because of involvement of various dynamic processes within the body and any prediction tool/method has limited applicability.

Keeping the merits and limitations of transcriptomics in mind, the present study was designed to determine if sex-different expression of genes coding for DMETs alone, could be used to predict sex-different drug metabolism of certain drugs, and, thus, provide a new tool for protecting susceptible subpopulations from possible adverse drug events.
Approximately 10% (29) of the 298 genes that encode DMETs were found to be expressed at significantly different levels in the livers of adult male and female F344 rats, suggesting possible differences in how drugs are metabolized by males and females. Twelve of these genes were more highly expressed in females and 17 were more highly expressed in males. Collectively, the enzymes encoded by these sexually dimorphic genes are involved in the metabolism of more than 600 drugs (Supplemental Table 2), indicating the importance of understanding the possible sex-effects on drug metabolism.

Based on the data from PharmaPendium, 41 drugs were found to be metabolized by only one or two Cyps and these were considered candidate drugs to determine if different levels of the mRNAs that code for their drug metabolizing enzymes translated into different drug metabolism rates. Eleven drugs were chosen that represented several drug classes and were metabolized by each of the sex-biased Cyps. Though the Cyp-drug association for these 11 drugs was initially obtained from PharmaPendium, a survey of literature reports allowed us to confirm such association, namely, azelastine (Imai et al., 1999), buspirone (Zhu et al., 2005), doxorubicin (Kivisto et al., 1995), fentanyl (Lotsch et al., 2013), glimepiride (Suzuki et al., 2006; Yang et al., 2018), irinotecan (Mathijssen et al., 2001), phenytoin (Franco and Perucca, 2015), pravastatin (Williams and Feely, 2002), tamsulosin (Franco-Salinas et al., 2010), tazarotene (Attar et al., 2003), and terfenadine (Ling et al., 1995) were mainly metabolized by the Cyp as indicated in the PharmaPendium. The metabolism of these drugs was evaluated in primary hepatocytes derived from the livers of adult male and female F344 rats.
Of the 11 drugs tested in hepatocytes, three (doxorubicin, irinotecan, and phenytoin) were not substantially metabolized and thus a determination of sex-different metabolism could not be reached. A fourth drug, tazarotene, was rapidly metabolized in both male and female hepatocytes. A literature search showed that this prodrug was metabolized by esterases to the active drug, tazarotenic acid (Madhu et al., 1997). Measurement of this reaction in the male and female hepatocytes showed that the esterases were not sexually dimorphic. Of the remaining seven drugs, six (83%), namely, azelastine, buspirone, fentanyl, glimepiride, tamsulosin, and terfenadine were found to be metabolized differently by male and female hepatocytes as predicted by the gene expression profiles and match the drug-Cyp association found in literature for humans (Ling et al., 1995; Imai et al., 1999; Zhu et al., 2005; Suzuki et al., 2006; Franco-Salinas et al., 2010; Lotsch et al., 2013). The seventh drug pravastatin, failed to show the predicted sexually dimorphic metabolism, although a relatively large, but not statistically significant, sex difference was observed. This may be explained in part because of insignificant metabolism of pravastatin by CYP3A subfamily, which metabolizes most of the statin drugs (Williams and Feely, 2002). Thus, simple measures of gene expression are sufficient to give a strong indication of sex-different drug metabolism, and the further evaluation of such drugs may benefit from increased attention to possible sex-differences in efficacy and adverse effects.

Thirty-three drugs were evaluated for cytotoxicity and were found to be generally non-toxic under the conditions used. Only one drug with sex-different metabolism, terfenadine, was found to be cytotoxic in primary rat hepatocytes. Terfenadine has been shown to be cytotoxic to primary hepatocytes of both rats and humans (Jurima-Romet et al., 1996) and the results presented here show less toxicity in hepatocytes from female rats, where metabolism of
Terfenadine was faster than in hepatocytes from male rats. Thus, in at least one case, sex-different drug metabolism resulted in sex-different toxicity.

Despite the high ability to predict sex-different drug metabolism based on DMET transcript profiles, four drugs did not meet our expectations of sex different metabolism because of incomplete knowledge of their basic metabolism. This was due to our efforts to standardize the analysis and hypothesis testing by relying exclusively on the knowledge base captured in PharmaPendium for making our predictions. We also, purposely, did not examine drug half-life information contained in the database to prevent unintentional bias. It is possible that examination of the half-life information in PharmaPendium would have alerted us to the long half-lives of doxorubicin, irinotecan, and phenytoin, and we could have eliminated them from our hypothesis testing in the 2 hr incubation with primary rat hepatocytes. A retrospective search of half-life information in the database showed doxorubicin to have the longest half-life (20-50 hr) among the 11 drugs. Moreover, a literature survey also indicated that doxorubicin is primarily metabolized into doxorubicinol by aldoketoreductases and that the CYP3A subfamily may play a role in doxorubicin metabolism (Kivisto et al., 1995). However, the half-lives of irinotecan and phenytoin overlapped with some of the remaining eight drugs so that we would not have excluded them based on this new information. Importantly, the half-life information in PharmaPendium is derived mainly from clinical studies, so a cross-species extrapolation may not always be accurate (Turpeinen et al., 2007). An in vivo pharmacokinetic study utilizing male and female F344 rats may allow the evaluation of metabolism of drugs with relatively long half-lives and allow the hypothesis testing of drugs with long half-lives. Tazarotene was rapidly metabolized to tazarotenic acid by esterase by both male and female hepatocytes and without a
sex difference. PharmaPendium did not contain information on the metabolism of tazarotene by esterase but listed tazarotene as an enzyme substrate of CYP2C8 (rat ortholog is Cyp2c7). Tazarotene is actually metabolized to tazarotenic acid by esterases and then tazarotenic acid is metabolized into a sulfoxide metabolite by CYP2C8 and FMOs (Flavin-containing MonoOxygenases) (Attar et al., 2003). Thus, although PharmaPendium contains much valuable regulatory information from drug approval packages, in future studies and applications of this method, improved accuracy may be obtained by using as much existing information as possible from all available sources.

These data suggest that possible sex differences in drug metabolism in the preclinical rat model during drug development may be computationally identified using existing Cyp gene expression profiles combined with the accruing knowledge of the candidate drug metabolism pathway. Any sex difference can then be confirmed by relatively high throughput cell metabolism studies using primary hepatocytes derived from male and female rats. Extension of this computational method to other classes of DMETs whose mRNA expression was sex-different, such as other phase 1 metabolizers, phase 2 metabolizers and drug transporters (Tables 2 and 3), would allow a more complete evaluation of sex-different metabolism. In addition, this method may be applicable to evaluation of other susceptible subpopulations such as children and the elderly. Children (Joseph et al., 2015; Germovsek et al., 2019) and the elderly (Rida et al., 2008; Herrera et al., 2010; Cho et al., 2011) are frequently not included in clinical trials so that the direct information needed to make benefit-risk assessments is often simply not available for these populations. Extrapolations are then made from results of studies performed in predominantly middle-age adult populations, even though changes in DMETs during development are known to occur (Hines, 2008). This
may lead to vulnerable patient populations being exposed to possibly ineffective therapies and unknown risks of adverse events (Hilmer and Gazarian, 2008). In the absence of direct clinical trial assessments of drug safety and efficacy in patients at the extremes of age, preclinical studies are often used to inform decision-making (FDA, 2006). Therefore, alternative methods are needed to identify potential drug safety issues in susceptible populations. Coupling drug metabolizing enzyme information with gene expression profiles of preclinical models during the life-span may allow better assessment of potential susceptibilities to adverse events.

One caveat of the present study is that drug transporters were not investigated. The two drugs tested in this study, pravastatin and glimepiride, are well-established substrates for organic anion transporting polypeptide transporters. However, the liver gene expressions of these transporters were not significantly different between male and female rats. Thus, the sex-biased difference in metabolism for these two drugs observed here is less likely to be caused by their transporters, though gene expression levels may not necessarily reflect the function levels of the corresponding proteins. Nevertheless, some genes for the ATP-binding cassette and the solute carrier (SLC) protein transporter families were indeed found to be differentially expressed between male and female rats (Table 2 and 3). Further studies are needed to elucidate the role of these transporters in sex-biased drug metabolism and toxicity.

Perhaps the largest benefit to drug evaluation would be to use human-derived gene expression data and drug metabolism knowledge, since Cyp enzyme activities are known to differ between humans and experimental animal species (Turpeinen et al., 2007). Currently, large human datasets of gene expression across multiple normal and diseased tissues, including the liver, of both sexes through the life span are not available. As these become available through efforts such as the Genotype-Tissue Expression Consortium (GTEx, 2015), direct application of this
method to humans will allow assessment of sex and age differences in drug metabolism that may lead to differences in drug efficacy or adverse events. The ability to identify sub-populations, based upon sex or age, with susceptibilities to adverse events will better inform the regulatory decisions that are made with regard to drugs and other FDA-regulated products.
Acknowledgements

We thank Dr. Jun Zhang for her help with the cytotoxicity assays and Ms. Carrie Moland for shipping samples. We also thank Dr. Amy Inselman for valuable suggestions on the manuscript.
Authorship Contributions

*Participated in research design:* Fuscoe, Shi, Vijay, Beger, Hanig.

*Conducted experiments:* Shi, Ren, Greenhaw, Han, Pence.

*Performed data analysis:* Vijay, Fuscoe, Han, Shi.

*Wrote or contributed to the writing of the manuscript:* Fuscoe, Shi, Han, Vijay.
References

Arrowsmith J (2011) Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 10:87.

Attar M, Dong D, Ling KH, and Tang-Liu DD (2003) Cytochrome P450 2C8 and flavin-containing monoxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos 31:476-481.

Beery AK and Zucker I (2011) Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35:565-572.

Cho S, Lau SW, Tandon V, Kumi K, Pfuma E, and Abernethy DR (2011) Geriatric drug evaluation: where are we now and where should we be in the future? Arch Intern Med 171:937-940.

Clayton JA and Collins FS (2014) Policy: NIH to balance sex in cell and animal studies. Nature 509:282-283.

Fang H, Harris SC, Su Z, Chen M, Qian F, Shi L, Perkins R, and Tong W (2009) ArrayTrack: an FDA and public genomic tool. Methods Mol Biol 563:379-398.

FDA (2006) U.S. Food and Drug Administration, Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products, www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf.

FDA (2013) U.S. Food and Drug Agency Drug Safety Communication, Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf.

FDA (2016) “ArrayTrack- a microarray database, data analysis and interpretation tool.” 2016, from https://www.fda.gov/science-research/bioinformatics-tools/arraytracktm-hca-pca-standalone-package-powerful-data-exploring-tools.

Franco-Salinas G, de la Rosette JJ, and Michel MC (2010) Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 49:177-188.

Franco V and Perucca E (2015) CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol 11:1269-1279.

GAO (2001) U.S. General Accounting Office, Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women, www.gao.gov/new.items/d01286r.pdf.

Germovsek E, Barker CIS, Sharland M, and Standing JF (2019) Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clin Pharmacokinet 58:39-52.

Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, and Shader RI (2004) Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 76:467-479.

GTEx Consortium (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348:648-660.

Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, and Weinberg AD (2010) Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health 100 Suppl 1:S105-112.
Hilmer SN and Gazarian M (2008) Clinical pharmacology in special populations: the extremes of age. *Expert Rev Clin Pharmacol* 1:467-469.

Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. *Pharmacol Ther* 118:250-267.

Imai T, Taketani M, Suzu T, Kusube K, and Otagiri M (1999) In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. *Drug Metab Dispos* 27:942-946.

Institute of Medicine (2010) Women’s Health Research: Progress, Pitfalls, and Promise. *National Academies Press*.

Joseph PD, Craig JC, and Caldwell PH (2015) Clinical trials in children. *Br J Clin Pharmacol* 79:357-369.

Jurima-Romet M, Huang HS, Beck DJ, and Li AP (1996) Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. *Toxicol In Vitro* 10:655-663.

Karczewski KJ and Snyder MP (2018) Integrative omics for health and disease. *Nat Rev Genet* 19:299-310.

Kivisto KT, Kroemer HK, and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. *Br J Clin Pharmacol* 40:523-530.

Kweklo JC, Desai VG, Moland CL, Branham WS, and Fuscoe JC (2010) Age and sex dependent changes in liver gene expression during the life cycle of the rat. *BMC Genomics* 11:675.

Kweklo JC, Desai VG, Moland CL, Vijay V, and Fuscoe JC (2013a) Life cycle analysis of kidney gene expression in male F344 rats. *PLoS One* 8:e75305.

Kweklo JC, Desai VG, Moland CL, Vijay V, and Fuscoe JC (2013b) Sex differences in kidney gene expression during the life cycle of F344 rats. *Biol Sex Differ* 4:14.

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680-685.

Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, and Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. *Drug Metab Dispos* 23:631-636.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.

Lotsch J, Walter C, Parnham MJ, Oertel BG, and Geisslinger G (2013) Pharmacokinetics of non-intravenous formulations of fentanyl. *Clin Pharmacokinet* 52:23-36.

Madhu C, Duff S, Baumgarten V, Rix P, Small D, and Tang-Liu D (1997) Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. *J Pharm Sci* 86:972-974.

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). *Clin Cancer Res* 7:2182-2194.

McIntyre IM (2014) Liver and peripheral blood concentration ratio (L/P) as a marker of postmortem drug redistribution: a literature review. *Forensic Sci Med Pathol* 10:91-96.

Moore TJ, Cohen MR, and Furberg CD (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. *Arch Intern Med* 167:1752-1759.

NIH (1994) National Institutes of Health, Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, [http://grants.nih.gov/grants/guide/notice-files/not94-100.html](http://grants.nih.gov/grants/guide/notice-files/not94-100.html).
NIH (2000) National Institutes of Health, Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, http://grants1.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.

Paech F, Abegg VF, Duthaler U, Terracciano L, Bouitbir J, and Krahenbuhl S (2018) Sunitinib induces hepatocyte mitochondrial damage and apoptosis in mice. *Toxicology* 409:13-23.

Ridda I, Lindley R, and MacIntyre RC (2008) The challenges of clinical trials in the exclusion zone: the case of the frail elderly. *Australas J Ageing* 27:61-66.

Shi Q, Yang X, Greenhaw J, and Salminen WF (2011) Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes. *Toxicol Sci* 122:579-586.

Soldin OP, Chung SH, and Mattison DR (2011) Sex differences in drug disposition. *J Biomed Biotechnol* 2011:187103.

Soldin OP and Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet* 48:143-157.

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, and Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. *Diabetes Res Clin Pract* 72:148-154.

Tong W, Cao X, Harris S, Sun H, Fang H, Fuscoe J, Harris A, Hong H, Xie Q, Perkins R, Shi L, and Casciano D (2003) ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. *Environ Health Perspect* 111:1819-1826.

Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, and Pasanen M (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. *Xenobiotica* 37:1367-1377.

van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, and Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415:530-536.

Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, and Talal AH (2017) Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. *Antimicrob Agents Chemother* 61:e02283-02216.

Waxman DJ and Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. *Mol Pharmacol* 76:215-228.
Weng Z, Luo Y, Yang X, Greenhaw JJ, Li H, Xie L, Mattes WB, and Shi Q (2015) Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis. *Toxicology* 327:10-21.

Williams D and Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. *Clin Pharmacokinet* 41:343-370.

Yang F, Xiong X, Liu Y, Zhang H, Huang S, Xiong Y, Hu X, and Xia C (2018) CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. *Sci Rep* 8:10994.

Yang L, Li Y, Hong H, Chang CW, Guo LW, Lyn-Cook B, Shi L, and Ning B (2012) Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver. *J Drug Metab Toxicol* 3:1000119.

Yu Y, Fuscoe JC, Zhao C, Guo C, Jia M, Qing T, Bannon DI, Lancashire L, Bao W, Du T, Luo H, Su Z, Jones WD, Moland CL, Branham WS, Qian F, Ning B, Li Y, Hong H, Guo L, Mei N, Shi T, Wang KY, Wolfinger RD, Nikolsky Y, Walker SJ, Duerksen-Hughes P, Mason CE, Tong W, Thierry-Mieg J, Thierry-Mieg D, Shi L, and Wang C (2014) A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages. *Nature communications* 5:3230.

Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* 138:103-141.

Zhang J, Ren L, Yang X, White M, Greenhaw J, Harris T, Wu Q, Bryant M, Papoian T, Mattes W, and Shi Q (2018) Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. *Toxicol Lett* 291:138-148.

Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, and Mitroka J (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. *Drug Metab Dispos* 33:500-507.

Zucker I and Beery AK (2010) Males still dominate animal studies. *Nature* 465:690.
Footnotes

The abstract was previously presented at the 2018 Organization for the Study of Sex Differences Annual Meeting with the following title and authors: Can Transcriptomic Profiles Be Used to Predict Sex-specific Drug Metabolism? by James C. Fuscoe, Qiang Shi, Tao Han, Lijun Ren, James J. Greenhaw, Joseph Hanig, Richard D. Beger, Lisa M. Pence, Laura K. Schnackenberg, Thomas C. Schmitt, Varsha G. Desai, Carrie L. Moland, and Vikrant Vijay.

This work was supported by the intramural research program of the Food and Drug Administration’s National Center for Toxicological Research and the Food and Drug Administration’s Office of Women’s Health [E075511].

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the FDA.

Reprint requests to: James C. Fuscoe, Ph.D., FDA-NCTR, 3900 NCTR Rd, Jefferson, AR 72079; Email: jfuscoe@gmail.com or Vikrant Vijay, Ph.D., FDA-NCTR, 3900 NCTR Rd, Jefferson, AR 72079; Email: vikrant.vijay@fda.hhs.gov.

This article has supplemental material.
Figure Legends

Figure 1. Principal component analysis of expression of 298 drug metabolism/transporter genes. Expression of hepatic drug metabolism genes varies with sex and age in untreated F344 rats. Each sphere represents the hepatic expression profile of a single rat, with females represented by black vertices and males without. Numbers and colors indicate age (wk). Arrowed line indicates trajectory of profiles with age for males (blue line) and females (red line). Dotted circles show large expression profile difference between males and females at ages of 8-52 wk.

Figure 2. Real-time quantitative PCR measurement of Cyp mRNAs in untreated suspension cultures of primary hepatocytes derived from male (solid line) and female (dashed line) F344 rats. (A) Cyp2c7, (B) Cyp3a62, (C) Cyp3a2, and (D) Cyp2c11 were measured at 0, 30, 60, 90 and 120 min of culture. Measurements were normalized to the lowest measured value for each Cyp and expressed as relative expression. Cyp mRNA levels were quantified in hepatocytes from three males and three females, and all measurements were made in duplicate. The average and standard error of the mean are shown for each culture time. Gapdh was used as the internal endogenous control. Males and females expressed significantly different levels of mRNA coding for Cyp2c7 (p<0.01), Cyp3a62 (p<10^-5), Cyp3a2 (p<10^-30), and Cyp2c11 (p<10^-28) by Student’s t-test.

Figure 3. Western blot analysis of CYP proteins in untreated suspension cultures of primary hepatocytes derived from male and female F344 rats. (A) CYP2C11 and (B) CYP3A2, along with a control protein, actin, were measured at 0, 30, 60, 90 and 120 min of culture. CYP
Figure 4. Metabolism of selected drugs during incubation with suspension cultures of primary hepatocytes derived from male (solid line) and female (dashed line) F344 rats. (A) azelastine, (B) buspirone, (C) doxorubicin, (D) fentanyl, (E) glimepiride, (F) irinotecan, (G) phenytoin, (H) pravastatin, and (I) tamsulosin were measured at 5, 15, 30, 60, 90 and 120 min of culture. Drug levels were measured in triplicate at each time in hepatocyte cultures derived from three male and three female rats. The average drug remaining in the culture and standard error of the mean are shown for both male and female at each culture time. Reliable measurements were not possible for buspirone at 120 min. For each drug, the average drug remaining at each time point was compared between the sexes using a one-tail t-test (* and ** indicate significant difference with p-value < 0.05 and < 0.01, respectively). The calculation of slope and testing for heterogeneity (or homogeneity) of the slopes of the regression lines between males and females were performed using a generalized linear model procedure (Proc GLM) as described in Materials and Methods. Males metabolized azelastine, buspirone, fentanyl, glimepiride, and tamsulosin significantly more rapidly than females (p< 0.01).

Figure 5. Metabolism of tazarotene and formation of tazarotenic acid from tazarotene in suspension cultures of primary rat hepatocytes derived from male (solid line) and female (dashed line) F344 rats. Drug levels were measured in triplicate at each time (5, 15, 30, 60, 90 and 120 min of culture) in hepatocyte cultures derived from three male and three female rats. The average
relative drug amount in the culture and standard error of the mean are shown for both male (filled square) and female (filled circle) at each culture time. The calculation of slope and testing for heterogeneity (or homogeneity) of the slopes of the regression lines between males and females were performed using a generalized linear model procedure (Proc GLM) as described in Materials and Methods. (A) No significant difference between males and females was seen in the metabolism of tazarotene. (B) No significant difference between males and females was seen in the metabolism of tazarotene to tazarotenic acid. Dotted line indicates the average of male and female relative tazarotenic acid levels.

Figure 6. Formation of fexofenadine from terfenadine in suspension cultures of primary rat hepatocytes derived from male (solid line) and female (dashed line) F344 rats. Fexofenadine levels were measured in triplicate at each time in hepatocyte cultures derived from three male and three female rats. The average drug remaining in the culture and standard error of the mean are shown for both male (filled square) and female (filled circle) at each culture time. The average drug remaining at each time point was compared between the sexes using a one-tail t-test (* and ** indicate significant difference with p-value < 0.05 and < 0.01, respectively). The calculation of slope and testing for heterogeneity (or homogeneity) of the slopes of the regression lines between males and females were performed using a generalized linear model procedure (Proc GLM) as described in Materials and Methods. Males metabolized terfenadine to fexofenadine significantly more rapidly than females (p< 0.0001).
Figure 7. Cytotoxicity of doxorubicin (A) and terfenadine (B). LDH release from hepatocytes was measured 24 hr after addition of the tested drugs (1x – 30x Cmax; Cmax is 110 ng/ml for doxorubicin and 229 ng/ml for terfenadine (Supplemental Table 3)) and cytotoxicity expressed as the percentage of total cellular LDH. Significant cytotoxicity compared to untreated control cultures is indicated by * (p< 0.05). Significant difference in cytotoxicity between male and female hepatocytes at corresponding times is indicated by # (p< 0.05). Shown are the average measurements and standard error of the mean for hepatocytes derived from three male (solid line) and three female (dashed line) F344 rats.
Table 1. Mass transitions and voltages for quantitation of drugs.

| Drug          | Q1 (m/z) | Q2 (m/z) | CE<sup>a</sup> (V) | Mode   |
|---------------|----------|----------|---------------------|--------|
| Azelastine    | 382.1    | 112.2    | 35                  | Positive |
| Buspirone     | 386.2    | 122.1    | 40                  | Positive |
| Doxorubicin   | 544.1    | 361.1    | 20                  | Positive |
| Fentanyl      | 337.2    | 188.2    | 50                  | Positive |
| Fexofenadine  | 502.2    | 171.1    | 49                  | Positive |
| Glimepiride   | 491.2    | 352.1    | 30                  | Positive |
| Irinotecan    | 587.2    | 124.2    | 45                  | Positive |
| Phenytoin     | 253.1    | 181.1    | 26                  | Positive |
| Pravastatin   | 423.2    | 321.2    | -20                 | Negative |
| Tamsulosin    | 410.2    | 229.1    | 30                  | Positive |
| Tazarotene    | 352.1    | 294.2    | 56                  | Positive |
| Tazarotenic Acid | 322.1  | 278.1    | -26                 | Negative |
| Terfenadine   | 472.2    | 436.2    | 30                  | Positive |

<sup>a</sup> Collision energy.
Table 2. Male-biased expression of genes encoding DMETs in liver of adult rats.

| Gene Symbol | Description                  | Human Ortholog | Number of Drugs\(^a\) | Fold-difference in Expression (M/F)\(^b\) |
|-------------|------------------------------|----------------|------------------------|------------------------------------------|
| Cyp3a2      | cytochrome P450              | CYP3A4         | 487                    | 2497                                     |
| Cyp2c11     | cytochrome P450              | CYP2C18        | 424                    | 2239                                     |
| Cyp2c13     | cytochrome P450              |                | 3                      | 1232                                     |
| Cyp2a2      | cytochrome P450              |                | 2                      | 237                                      |
| Sult1e1     | sulfotransferase             | SULT1E1        | 4                      | 216                                      |
| Slc22a8     | solute carrier               | SLC22A8        | 223                    | 46.9                                     |
| Car3        | carbonic anhydrase           | CA3            | 1                      | 30.4                                     |
| Cyp3a18     | cytochrome P450              |                | 2                      | 18.6                                     |
| Cyp4a2      | cytochrome P450              |                | 34                     | 18.6                                     |
| Akr1c3      | aldo-keto reductase          | AKR1C3         | 1                      | 16.8                                     |
| Hsd11b1     | hydroxysteroid 11-beta dehydrogenase 1 | HSD11B1 | 1 | 10.5 |
| Slc22a25    | solute carrier               | SLC22A25       | 53                     | 9.2                                      |
| Cyp4a8      | cytochrome P450              |                | 1                      | 8.8                                      |
| Cyp3a62     | cytochrome P450              |                | 224                    | 6.2                                      |
| Sult1c3     | sulfotransferase             | SULT1C3        | 2                      | 3.2                                      |
| Tymp        | thymidine phosphorylase      | TYMP           | 1                      | 3.0                                      |
| Pld1        | phospholipase D1             | PLD1           | 1                      | 2.5                                      |

\(^a\) Number of drugs metabolized by the enzyme/transporter. Drugs are listed in Supplemental Table 2.

\(^b\) Calculated from microarray data (Kwekel et al., 2010) as average of expression at 8, 15, 21, and 52 weeks of age.
Table 3. Female-biased expression of genes encoding DMETs in liver of adult rats.

| Gene Symbol | Description                  | Human Ortholog | Number of Drugs\(^a\) | Fold-difference in Expression (F/M)\(^b\) |
|-------------|------------------------------|----------------|------------------------|------------------------------------------|
| Cyp2c12     | cytochrome P450              |                | 4                      | 346                                      |
| Adh6        | alcohol dehydrogenase 6      | ADH6           | 10                     | 29.1                                     |
| Abcd2       | ATP-binding cassette         | ABCD2          | 1                      | 22.8                                     |
| Sult2a1     | sulfotransferase             | SULT2A1        | 4                      | 18.8                                     |
| Abcc3       | ATP-binding cassette         | ABCC3          | 23                     | 7.6                                      |
| Cyp3a9      | cytochrome P450              | CYP3A5         | 9                      | 6.3                                      |
| Prss32      | protease, serine, 32         |                | 1                      | 5.7                                      |
| Pla2g16     | phospholipase A2             | PLA2G16        | 1                      | 4.5                                      |
| Bche        | butyrylcholinesterase        | BCHE           | 2                      | 4.0                                      |
| Slc7a5      | solute carrier               | SLC7A5         | 2                      | 4.0                                      |
| Cyp2c7      | cytochrome P450              |                | 254                    | 3.2                                      |
| Ces2e       | carboxylesterase 2E          |                | 1                      | 2.8                                      |

\(^a\) Number of drugs metabolized by the enzyme/transporter. Drugs are listed in Supplemental Table 2.

\(^b\) Calculated from microarray data (Kwekel et al., 2010) as average of expression at 8, 15, 21, and 52 weeks of age.
Table 4. Forty-one drugs metabolized by sexually dimorphic Cyps.

| Drug                | Drug Class       | DMET 1 | DMET 2 | Drug                | Drug Class   | DMET 1 | DMET 2 |
|---------------------|------------------|--------|--------|---------------------|--------------|--------|--------|
| Amlodipine<sup>d</sup> | Ca Channel Blocker | Cyp3a2 | ~2500 M>F | Ketoprofen | NSAID       | Cyp2c11 | ~2200 M>F |
| Astemizole<sup>d, e</sup> | Antihistamine | Cyp3a2 | ~2500 M>F | Levobupivacaine<sup>d</sup> | Anesthetic, Local | Cyp3a2 | ~2500 M>F |
| Azelastine<sup>d, e</sup> | Antihistamine | Cyp2c11 | ~2200 M>F | Lidocaine<sup>d</sup> | Anesthetic, Local | Cyp3a2 | ~2500 M>F |
| Beclomethasone<sup>d, e</sup> | Corticosteroid | Cyp3a2 | ~2500 M>F | Loratadine<sup>d</sup> | Antihistamine | Cyp3a2 | ~2500 M>F |
| Buspirone<sup>d</sup> | Anxiolytic | Cyp3a2 | ~2500 M>F | Medroxyprogesterone<sup>d</sup> | Hormone | Cyp3a2 | ~2500 M>F |
| Cetirizine<sup>d</sup> | Antihistamine | Cyp3a2 | ~2500 M>F | Mometasone<sup>d</sup> | Corticosteroid | Cyp3a2 | ~2500 M>F | Cyp3a62 | ~6 M>F |
| Clonazepam | Antiepileptics | Cyp3a62 | ~6 M>F | Naproxen | NSAID | Cyp2c11 | ~2200 M>F |
| Dextromethorphan<sup>d, e</sup> | Cough Suppressant | Cyp3a62 | ~6 M>F | Nifedipine<sup>d, e</sup> | Ca Channel Blocker | Cyp3a2 | ~2500 M>F |
| Digoxin<sup>d</sup> | Cardiac Glycoside | Cyp3a2 | ~2500 M>F | Nimodipine<sup>d, e</sup> | Ca Channel Blocker | Cyp3a2 | ~2500 M>F |
| Drug                | Class               | Enzyme | IC50  | Sex     |
|---------------------|---------------------|---------|-------|---------|
| Doxorubicin         | Antineoplastic      | Cyp3a2  | ~2500 | M>F     |
| Norethindrone       | Hormone             | Cyp3a2  | ~2500 | M>F     |
| Ebastine            | Antihistamine       | Cyp3a2  | ~2500 | M>F     |
| Oxybutynin          | Anticholinergic     | Cyp3a2  | ~2500 | M>F     |
| Ethinyl Estradiol   | Hormone             | Cyp3a62 | ~6    | M>F     |
| Phentermine         | Antiobesity         | Cyp3a2  | ~2500 | M>F     |
| Etonogestrel        | Hormone             | Cyp3a2  | ~2500 | M>F     |
| Phenytoin           | Antiepileptic       | Cyp3a11 | ~2200 | M>F     |
| Fentanyl            | Analgesics          | Cyp3a62 | ~6    | M>F     |
| Pravastatin         | Lipid Modifying     | Cyp3a2  | ~2500 | M>F     |
| Fexofenadine        | Antihistamine       | Cyp3a62 | ~6    | M>F     |
| Sertindole          | Antipsychotic       | Cyp3a62 | ~6    | M>F     |
| Flunisolide         | Corticosteroid      | Cyp3a2  | ~2500 | M>F     |
| Tamsulosin          | Antiadrenergic      | Cyp3a2  | ~2500 | M>F     |
| Fosphenytoin        | Antiepileptic       | Cyp2c11 | ~2200 | M>F     |
| Tazarotene          | Antipsoriatic       | Cyp2c7  | ~3    | F>M     |
| Glimepiride         | Antihyperglycemic   | Cyp2c11 | ~2200 | M>F     |
| Terfenadine         | Antihistamine       | Cyp3a2  | ~2500 | M>F     |
| Hydrocodone         | Analgesics          | Cyp3a2  | ~2500 | M>F     |
| Trazodone           | Antidepressant      | Cyp3a2  | ~2500 | M>F     |
| Ibutide             | Antiarrhythmic      | Cyp3a2  | ~2500 | M>F     |
| Triazolam           | Anti-Anxiety        | Cyp3a62 | ~6    | M>F     |
Irinotecan\textsuperscript{d,e} Antineoplastic \textit{Cyp3a2} \sim 2500 M>F

\textsuperscript{a} Fold-difference in gene expression level.
\textsuperscript{b} Expression is higher in males than females.
\textsuperscript{c} Expression is higher in females than males.
\textsuperscript{d} 33 drugs tested for cytotoxicity in hepatocytes from one male and one female F344 rat.
\textsuperscript{e} 19 drugs selected for cytotoxicity testing in hepatocytes from a total of three male and three female F344 rats.
Table 5. Half-lives of seven drugs in male and female primary rat hepatocytes.

| Drug      | Rat sex | T_{1/2} (min)^a | P-value^b |
|-----------|---------|-----------------|-----------|
| Azelastine| Male    | 61±7            | 0.042     |
|           | Female  | 107±34          |           |
| Buspirone | Male    | 70±11           | 0.023     |
|           | Female  | 132±36          |           |
| Fentanyl  | Male    | 35±2            | 0.002     |
|           | Female  | 52±5            |           |
| Glimepiride| Male | 194±74         | 0.027     |
|           | Female  | 329±45          |           |
| Tamsulosin| Male   | 31±1            | 0.018     |
|           | Female  | 43±6            |           |
| Pravastatin| Male | 263±265        | 0.481     |
|           | Female  | 255±77          |           |
| Tazarotene| Male   | 17±2            | 0.281     |
|           | Female  | 16±2            |           |

^a Mean ± standard deviation.

^b Comparison of drug half-life in males and females.
Figures
Fig 1.
Fig 2.
Fig 3.
Fig 4.
Fig 5.
Fig 6.
Fig 7.